Delhi High Court Finds Fortis Healthcare Liable for Disappearing Promoter Shares

BANKINGFINANCE
Whalesbook Logo
AuthorIshaan Verma|Published at:
Delhi High Court Finds Fortis Healthcare Liable for Disappearing Promoter Shares
Overview

The Delhi High Court has ruled Fortis Healthcare Ltd. responsible for shares that disappeared from former promoters Malvinder and Shivinder Singh. The court stated Fortis cannot evade liability for these shares, which are now central to Daiichi Sankyo's Rs 5,200 crore arbitration award enforcement case. Proceedings have been ongoing since December 2025.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Fortis Healthcare Held Responsible for Missing Shares

The Delhi High Court has declared Fortis Healthcare Ltd. (FHL) liable for the disappearance of shares previously held by former promoters Malvinder and Shivinder Singh. Justice Subramonium Prasad stressed that FHL should have intervened when the shares were sold, establishing the company's accountability.

Daiichi Sankyo's Rs 5,200 Crore Enforcement Case

This ruling comes amid Daiichi Sankyo's ongoing effort to enforce an arbitration award against the Singh brothers, totaling approximately Rs 5,200 crore. The award originates from Daiichi Sankyo's purchase of Ranbaxy Laboratories. The High Court has been reviewing the case since December 2025, signaling a strong commitment to upholding international arbitration decisions.

Dispute Over Collateral Shares

The legal dispute involves the Singh brothers, sixteen banks, and Fortis Healthcare, focusing on 38.3 million shares that served as collateral for the arbitration award. Daiichi Sankyo is pursuing a forensic audit of FHL and the banks to examine their role in the sale of assets once valued significantly higher. FHL also plans to file a response to Daiichi Sankyo's perjury allegations.

Market Performance Context

Fortis Healthcare Ltd. has a market capitalization of roughly ₹72,525 crore. As of May 2026, its P/E ratio ranges from 65.0 to 76.07. Recent Q3 FY26 results showed revenue growth and improved EBITDA margins, indicating strong operational performance.

Legal Challenges and Risks

Ongoing legal issues concerning the Singh brothers continue to affect Fortis Healthcare. Past allegations of fund diversion and the current arbitration award enforcement have led to intense scrutiny. The Supreme Court previously ordered jail time and forensic audits for the Singh brothers related to Fortis deals. SEBI has also fined and restricted the Singh brothers due to fund diversion charges involving Fortis Healthcare. The auctioning of the Fortis trademark by the Delhi High Court in October 2024 to recover part of the award highlights the financial risks tied to these disputes.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.